Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of sovateltide in acute ischemic stroke
2024-519551-29-00Phase 3Authorised
- Sponsor
- Pharmazz, Inc.
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Sovateltide with Placebo comparator (2 arms). Primary endpoint: Good functional outcome by modified Rankin Scale at day 90. Planned start Aug 2025; status: authorised.
02
Drugs
sovateltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-519551-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519551-29-00.